Tag: 200-300

On March 28, 2019, Wailes, Jeffrey Steven; Briggs, Emma; Carter, Neil Brian; Morris, Melloney; Tate, Joseph Andrew published a patent.Related Products of 785777-98-2 The title of the patent was Preparation of pyrimidinyl carbamate or urea derivatives as herbicides. And the patent contained the following:

The present invention relates to herbicidally active pyridyl-(or pyrimidyl-) pyrimidine derivatives I [X1 = N or CR1; R1 = H, halo, CN, etc.; R2 = halo, CN, NO2, etc.; R3 = C(O)X2R12; X2 = O or NR10; R4 = H, alkyl, alkoxy, etc.; when X2 = O, R12 = alkyl, alkoxyalkyl, haloalkyl, etc.; when X2 = NR10, R12 = H, alkyl, alkoxy, etc.; R10 = (independently) H, alkyl, cycloalkyl; n = 0-1] or salts or N-oxides thereof, as well as to processes and intermediates used for the preparation of such derivatives E.g., a 2-step synthesis of II, starting from 2-chloro-4-methylpyrimidine-5-carboxylic acid, was described. Exemplified compounds I were evaluated for their pre-emergence and post-emergence herbicidal activities (data given). The invention further extends to herbicidal compositions comprising such derivatives I, as well as to the use of I and compositions in controlling undesirable plant growth: in particular the use in controlling weeds, in crops of useful plants. The experimental process involved the reaction of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine(cas: 785777-98-2).Related Products of 785777-98-2

The Article related to pyrimidinyl pyridylpyrimidinyl pyrimidylpyrimidinyl carbamate urea preparation herbicide, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Related Products of 785777-98-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Okafor, Charles O.; Steenberg, Marie L.; Buckley, Joseph P. published an article in 1977, the title of the article was Studies in the heterocyclic series. XIII. New CNS-depressants derived from 1,9-diazaphenoxazine and two isomeric triazaphenothiazine ring systems.Application In Synthesis of 5-Bromo-2,4,6-trichloropyrimidine And the article contains the following content:

Triazaphenothiazines I (R = NH2, H, SMe, OMe; R1 = NH2, Me, Cl, OH, OMe) and II (R = H, NH2, Cl; R1 = NH2, OH, Cl; R2 = MeO, Cl) were prepared in 78-93% yield. Reaction of 2-amino-3-mercapto-6-picoline with 2-amino-5-bromo-4-chloro-6-methylpyrimidine in the presence of H2SO4 and Na2SO3 gave 77% I (R = NH2, R1 = Me). All I and II showed appreciable CNS depressant activities comparable with the activity of chlorpromazine when tested in mice and rats; I (R = H, R1 = NH2) and II (R = R1 = Cl, R2 = MeO) were the most promising. All I and II decreased motor activity and rate of respiration within 30 min and body temperature was decreased by 0.5-1.9° compared to 0.8° with chlorpromazine. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Application In Synthesis of 5-Bromo-2,4,6-trichloropyrimidine

The Article related to depressant triazaphenothiazine, triazaphenothiazine, phenothiazine triaza, Heterocyclic Compounds (More Than One Hetero Atom): Thiazines (Including Cephalosporins) and other aspects.Application In Synthesis of 5-Bromo-2,4,6-trichloropyrimidine

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 20, 2003, Neya, Masahiro; Sawada, Akihiko; Ohne, Kazuhiko; Abe, Yoshito; Mizutani, Tsuyoshi; Ishibashi, Naoki; Inoue, Makoto published a patent.COA of Formula: C10H7BrN2 The title of the patent was Preparation of 2-(thiophenyl)thiopyran-1,1-dioxides as MMP or TNF-α inhibitors. And the patent contained the following:

Title compounds I [wherein R1 = (un)substituted Ph, naphthyl, bicyclic heterocyclyl, alkenyl, or alkynyl; R2 = CO2H or protected CO2H; or a salt thereof] were prepared as matrix metalloproteinase (MMP) or tumor necrosis factor α (TNF-α) inhibitors. For example, coupling of 2-(trimethylsilyl)ethyl (S)-[2-(5-bromothiophen-2-yl)-1,1-dioxo-3,4,5,6-tetrahydro-2H-thiopyran-2-yl]acetate and 2-(4′-cyano-4-biphenylyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane followed by deesterification gave II. Five compounds of the invention were tested for gelatinolytic activity against human MMP-9 and displayed inhibitory activity with IC50 values ranging from 1.37 nM to 16.0 nM. Thus, I are useful for treating and/or preventing diseases mediated by MMP or TNF-α (no data). The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).COA of Formula: C10H7BrN2

The Article related to thiophenyl thiopyrandioxide preparation mmp tnf inhibitor, Heterocyclic Compounds (One Hetero Atom): Thiopyrans and Areno- and Diarenothiopyrans and other aspects.COA of Formula: C10H7BrN2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Hou, Gui-Ge; Zhao, Hui-Juan; Sun, Ju-Feng; Lin, Dong; Dai, Xian-Ping; Han, Jing-Tian; Zhao, Hui published an article in 2013, the title of the article was Synthesis, structure and luminescence of Co-crystals with hexagonal channels: arranging disposition and π-π interactions.Synthetic Route of 160377-42-4 And the article contains the following content:

Co-crystallization of asym. building blocks 5-(4-pyridyl)pyrimidine (A) and 5-(4-(1-imidazolyl)phenyl)pyrimidine (B) with resorcinol and hydroquinone, resp., was studied. Four new organic co-crystals (1-4) were generated. The x-ray single crystal anal. indicates that the crystal packing in 1, 2 and 4 generates open hexagonal channels with resorcinol or hydroquinone mols. encapsulated through hydrogen bonding interactions. In 3, {B2(resorcinol)2} macrocycle is generated from clip-like resorcinol and asym. B mols. The luminescent properties of A, B and 1-4 were studied primarily in the solid state. The luminescent property is dependent on the mol. vertical arranging disposition and the intermol. π-π contacting characteristic. The results display more interesting tunability of the emission intensity of the building modules by the incorporation of coformers into the co-crystals. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).Synthetic Route of 160377-42-4

The Article related to preparation structure luminescence cobalt crystal hexagonal arranging disposition, Physical Organic Chemistry: Acid-Base, Tautomerism, and Other Equilibrium Studies and other aspects.Synthetic Route of 160377-42-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 20, 2016, Noh, Hyo-Jin; Yoon, Kyung-Jin; Yoon, Dae-Wi; Shin, In-Ae; Kim, Jun-Yun published a patent.Application of 160377-42-4 The title of the patent was Space-through charge transfer compound, and organic light emitting diode and display device using the same. And the patent contained the following:

Discussed is a space-through charge transfer compound for OLEDs exhibiting thermally activated delayed fluoroscence. The compound includes a naphthalene core; an electron donor moiety D selected from carbazole and phenylcarbazole; and an electron acceptor moiety A selected from pyridine, diazine, triazole and Ph benzodiazole, wherein the electron donor moiety and the electron acceptor moiety are combined to first and eighth positions of the naphthalene core with a benzene linker, resp., according to the following formula:. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).Application of 160377-42-4

The Article related to charge transfer compound light emitting diode, Electric Phenomena: Photoconductivity, Photoconductors, Photovoltaic Effect, Photoelectric Devices and other aspects.Application of 160377-42-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 4, 2019, Duvey, Guillaume; Celanire, Sylvain published a patent.Formula: C8H10BrN3O The title of the patent was Preparation of novel heterocyclic compounds 1-oxo-5,6,7,8-tetrahydro-2H-phthalazine derivatives and analogs, as mGluR7 modulators. And the patent contained the following:

The invention is related to the preparation of compounds I [G = N, CR7; E = N, CR8; provided that at least one of G or E is N; Y = CR9, N; X = (CR5R6)n; R1-9 = independently H, halo, CN, CF3, etc.; wherein any two radicals R1 and R2, R3 and R4, and R5 and R6 may be taken together to form an oxo; wherein optionally any two radicals selected from R1-9 may be taken together to form an (un)substituted 3 to 10-membered non aromatic carbocyclic or heterocyclic ring or a 5 to 10-membered aromatic heterocyclic ring; n = 0-1; Ar1, Ar2 = (un)substituted aryl or heteroaryl], their N-oxide forms , their pharmaceutically acceptable salts and solvates, their optical isomers, racemates, diastereoisomers, enantiomers and tautomers which are modulators of the metabotropic glutamate receptors (mGluR), preferably of the metabotropic glutamate receptor subtype 7 (mGluR7), to pharmaceutical composition comprising such compound and to their use for the treatment of prevention of disorders associated with glutamate dysfunction. Thus, II was prepared by a multi-step synthesis from 1-bromo-2,4-dimethylbenzene and 1,4-dioxaspiro[4.5]decan-8-one. Compounds I are antagonists or neg. allosteric modulators of the mGluR7 as they reduce or inhibit the mGluR7 response induced by glutamate or a mGluR7 agonist, such as L-AP4 as shown in an inositol monophosphate production assay. The experimental process involved the reaction of 4-(2-Bromopyrimidin-4-yl)morpholine(cas: 1209459-32-4).Formula: C8H10BrN3O

The Article related to oxotetrahydrophthalazine cyclopentapyridazinone pyridopyrimidinone preparation metabotropic glutamate receptor mglur7 modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.Formula: C8H10BrN3O

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 27, 2019, Duvey, Guillaume; Celanire, Sylvain published a patent.SDS of cas: 1209459-32-4 The title of the patent was Preparation of novel heterocyclic compounds 1-oxo-5,6,7,8-tetrahydro-2H-phthalazine derivatives and analogs, as mGluR7 modulators. And the patent contained the following:

The invention is related to the preparation of compounds I [G = N, CR7; E = N, CR8; provided that at least one of G or E is N; Y = CR9, N; X = (CR5R6)n; R1-9 = independently H, halo, CN, CF3, etc.; wherein any two radicals R1 and R2, R3 and R4, and R5 and R6 may be taken together to form an oxo; wherein optionally any two radicals selected from R1-9 may be taken together to form an (un)substituted 3 to 10-membered non aromatic carbocyclic or heterocyclic ring or a 5 to 10-membered aromatic heterocyclic ring; n = 0-1; Ar1, Ar2 = (un)substituted aryl or heteroaryl], their N-oxide forms , their pharmaceutically acceptable salts and solvates, their optical isomers, racemates, diastereoisomers, enantiomers and tautomers which are modulators of the metabotropic glutamate receptors (mGluR), preferably of the metabotropic glutamate receptor subtype 7 (mGluR7), to pharmaceutical composition comprising such compound and to their use for the treatment of prevention of disorders associated with glutamate dysfunction. Thus, II was prepared by a multi-step synthesis from 1-bromo-2,4-dimethylbenzene and 1,4-dioxaspiro[4.5]decan-8-one. Compounds I are antagonists or neg. modulators of the mGluR7 as they reduce or inhibit the mGluR7 response induced by glutamate or a mGluR7 agonist, such as L-AP4 as shown in an inositol monophosphate production assay. The experimental process involved the reaction of 4-(2-Bromopyrimidin-4-yl)morpholine(cas: 1209459-32-4).SDS of cas: 1209459-32-4

The Article related to oxotetrahydrophthalazine cyclopentapyridazinone pyridopyrimidinone preparation metabotropic glutamate receptor mglur7 modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyridazines, Cinnolines, and Phthalazines and other aspects.SDS of cas: 1209459-32-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On December 27, 2018, Luo, Zhi; Li, Xiaolin; Yang, Yaxun; Yang, Lele; Li, Peng; He, Haiying; Li, Jian; Chen, Shuhui published a patent.SDS of cas: 1209459-32-4 The title of the patent was Preparation of 3-halo-2-(aryloxymethyl)allylamine derivatives useful as semicarbazide-sensitive amine oxidase (SSAO) inhibitors for the treatment of nonalcohol steatohepatitis. And the patent contained the following:

The invention relates to 3-halo-2-(aryloxymethyl)allylamine derivatives of formula I, method for their preparation and their use as semicarbazide-sensitive amine oxidase (SSAO) inhibitors for the treatment of nonalc. steatohepatitis. Compounds of formula I, wherein one of R4 and R5 is H and another is F, Cl, Br and I; R1 is H, halo, CO2H, (un)substituted Ph, etc.; L1 is a bond, SO2O, NHCO, NH, etc.; n is 0 to 3; R is H, F, Cl, CONH2, etc.; ring A is R substituted 5- to 6-membered heterocycle, Ph and 5- to 9-membered heteroaryl, and their pharmaceutically acceptable salts, are claimed. Example compound II was prepared via a multistep procedure (procedure given). All the invention compounds were evaluated for their VAP-1/SSAO inhibitory activity. From the assay, it was determined that example compound II exhibited IC50 value of 0.3 nM towards VAP-1/SSAO. The experimental process involved the reaction of 4-(2-Bromopyrimidin-4-yl)morpholine(cas: 1209459-32-4).SDS of cas: 1209459-32-4

The Article related to haloaryloxymethylallylamine preparation ssao inhibitor treatment nonalc steatohepatitis, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Ethers, Sulfides, and The Corresponding Onium Compounds and other aspects.SDS of cas: 1209459-32-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 5, 2019, Xing, Qifeng; Li, Zhiyang; Liu, Shuyao; Ren, Xueyan published a patent.Recommanded Product: 160377-42-4 The title of the patent was 2,6,9,10-Tetrasubstituted anthracene compound, and its application in organic light-emitting device. And the patent contained the following:

The inventive organic light-emitting device comprises a substrate, an anode layer, a 2,6,9,10-tetrasubstituted anthracene compound-containing organic functional layer (I; where Ar1 is a substituted or unsubstituted nitrogen containing heteroaryl group; Ar3 is a substituted or unsubstituted Ph, naphthyl, or biphenyl group; Ar2 is a substituted or unsubstituted aryl or ring group; and R1 can be a hydrogen, alkyl, halogen, nitro, cyano, or aryl group) and a cathode layer. The organic functional layer comprises a hole injection layer, a hole transport layer, a light emitting layer, an electron transport layer, and an electron injection layer. One 2,6,9,10-tetrasubstituted anthracene compound (A1: 2,2′-((2,6-diphenylanthracene-9,10-diyl)bis(4,1-phenylene))dipyridine) is prepared by (1) stirring 2,6-dibromoanthracene-9,10-dione, phenylboronic acid, potassium carbonate, Pd2(dba)3, toluene, ethanol, and water under protection of nitrogen gas, heating to 100°C, and reacting under reflux for 12 h to obtain intermediate M2; (2) adding 2-(4-bromophenyl)pyridine and THF in a reactor, stirring, cooling to (-90)-(-80)°C, dropwise adding Bu lithium in 30 min, adding the intermediate M2, and stirring at room temperature for 8 h to obtain intermediate M3; (3) adding acetic acid in a reactor, stirring, heating to 60°C, adding the intermediate M3, KI, and sodium dihydrogen phosphate, and reacting under reflux at 120°C for 5 h. The invention has good voltage, efficiency and long service life. The experimental process involved the reaction of 5-(4-Bromophenyl)pyrimidine(cas: 160377-42-4).Recommanded Product: 160377-42-4

The Article related to organic light emitting device tetrasubstituted anthracene, Optical, Electron, and Mass Spectroscopy and Other Related Properties: Spectrometers and Optical Apparatus and other aspects.Recommanded Product: 160377-42-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 4, 2010, Marhold, Albrecht; Ebenbeck, Wolfgang; Knauer, Stephan published a patent.Computed Properties of 785777-98-2 The title of the patent was Preparation of polyfluoro-N-heteroaromatics. And the patent contained the following:

A process for the preparation of title compounds I [X = N-heteroaromatic with provisos; A = fluoroalkyl, fluoroalkoxy, fluoroalkylthio; R1 = (R1′)n; R1′ = alkyl, aryl, arylalkyl; n = 0-1; Y = (Y’)m; Y’ = Cl, Br, F; m = 1-3] was disclosed. For example, HF/Autoclave(150°C) mediated fluorination of 2,4-dichloro-5-trichloropyrimidine afforded claimed polyfluoro-N-heteroaromatic II in 68% yield. The experimental process involved the reaction of 2,5-Dichloro-4-(trifluoromethyl)pyrimidine(cas: 785777-98-2).Computed Properties of 785777-98-2

The Article related to polyfluoropyrazine preparation fluorination, polyfluoropyrimidine preparation fluorination, polyfluoropyridazine preparation fluorination, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Computed Properties of 785777-98-2

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia